These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 150989)
21. Recombination of fragments of human growth hormone: altered activity profile of the recombinant molecule. Reagan CR; Kostyo JL; Mills JB; Gennick SE; Messina JL; Wagner SA; Wilhelmi AE Endocrinology; 1981 Nov; 109(5):1663-71. PubMed ID: 7297498 [No Abstract] [Full Text] [Related]
22. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525 [TBL] [Abstract][Full Text] [Related]
23. Long-term administration of PACAP receptor antagonist, PACAP(6-27), impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice. Green BD; Irwin N; Cassidy RS; Gault VA; Flatt PR Peptides; 2006 Sep; 27(9):2343-9. PubMed ID: 16730098 [TBL] [Abstract][Full Text] [Related]
24. Nonmammalian growth hormones have diabetogenic and insulin-like activities. Cameron CM; Kostyo JL; Papkoff H Endocrinology; 1985 Apr; 116(4):1501-5. PubMed ID: 3882411 [TBL] [Abstract][Full Text] [Related]
25. Increased sensitivity to insulin-releasing and glucoregulatory effects of dynorphin A1-13 and U 50488h in ob/ob versus lean mice. Khawaja XZ; Green IC; Thorpe JR; Bailey CJ Diabetes; 1990 Oct; 39(10):1289-97. PubMed ID: 1976559 [TBL] [Abstract][Full Text] [Related]
26. Immunoreactive C-peptide in spontaneous syndromes of obesity and diabetes in mice. Flatt PR; Bailey CJ; Hampton SM; Swanston-Flatt SK; Marks V Horm Metab Res; 1987 Jan; 19(1):1-5. PubMed ID: 3549500 [TBL] [Abstract][Full Text] [Related]
27. Evidence that the N-terminus of human growth hormone is involved in expression of its growth promoting, diabetogenic, and insulin-like activities. Towns R; Kostyo JL; Vogel T; Sakal E; Tchelet A; Maher R; Gertler A Endocrinology; 1992 Mar; 130(3):1225-30. PubMed ID: 1537288 [TBL] [Abstract][Full Text] [Related]
28. Insulin releasing effects of adrenocorticotropin (ACTH 1-39) and ACTH fragments (1-24 and 18-39) in lean and genetically obese hyperglycaemic (ob/ob) mice. Bailey CJ; Flatt PR Int J Obes; 1987; 11(2):175-81. PubMed ID: 3038765 [TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737 [TBL] [Abstract][Full Text] [Related]
30. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice. O'Harte FP; Franklin ZJ; Irwin N Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150 [TBL] [Abstract][Full Text] [Related]
31. Increased sensitivity of adipose tissue to insulin after in vivo treatment of yellow Avy/A obese mice with amino-terminal peptides of human growth hormone. Frigeri LG; Teguh C; Ling N; Wolff GL; Lewis UJ Endocrinology; 1988 Jun; 122(6):2940-5. PubMed ID: 3131129 [TBL] [Abstract][Full Text] [Related]
32. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice. Parker JC; Irwin N; Lavery KS; Green BD; O'Harte FP; Gault VA; Flatt PR Biol Chem; 2007 Feb; 388(2):221-6. PubMed ID: 17261085 [TBL] [Abstract][Full Text] [Related]
33. Effects of the amino-terminal portion of human growth hormone on glucose clearance and metabolism in normal, diabetic, hypophysectomized, and diabetic-hypophysectomized rats. Salem MA Endocrinology; 1988 Sep; 123(3):1565-76. PubMed ID: 3042372 [TBL] [Abstract][Full Text] [Related]
34. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice. Lee EY; Kim YW; Oh H; Choi CS; Ahn JH; Lee BW; Kang ES; Cha BS; Lee HC Metabolism; 2014 Jun; 63(6):793-9. PubMed ID: 24684824 [TBL] [Abstract][Full Text] [Related]
35. The stimulatory effect of insulin on diacylglycerol generation in adipocyte membranes from ob/ob mice is impaired by growth hormone. Towns R; Kostyo JL; Martin D; Chou SY; Bennink MR Endocrinology; 1993 Apr; 132(4):1671-6. PubMed ID: 8462467 [TBL] [Abstract][Full Text] [Related]
36. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840 [TBL] [Abstract][Full Text] [Related]
37. Development of glucose intolerance and impaired plasma insulin response to glucose in obese hyperglycaemic (ob/ob) mice. Flatt PR; Bailey CJ Horm Metab Res; 1981 Oct; 13(10):556-60. PubMed ID: 7028589 [TBL] [Abstract][Full Text] [Related]
38. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice. Irwin N; Montgomery IA; Moffett RC; Flatt PR Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436 [TBL] [Abstract][Full Text] [Related]
39. A method for the study of the diabetogenic activity of pituitary growth hormone preparations in the rat. BOGDONOFF MD; SCHERR EH; LISTER L; OWEN JA; ENGEL FL Endocrinology; 1955 Sep; 57(3):272-85. PubMed ID: 13251231 [No Abstract] [Full Text] [Related]
40. [Diabetogenic action of the pituitary growth hormone]. HOUSSAY BA; RODRIGUEZ RR; CARDEZA AF C R Seances Soc Biol Fil; 1954 May; 148(9-10):910-1. PubMed ID: 13219834 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]